Grant: CIHR Fellowship
Direct Payment
$150,000.00
Comparative genetic and proteomic analysis of late-outgrowth endothelial progenitor cells from pulmonary arterial hypertension patients bearing mutations in bone morphogenetic protein receptor type II
EF 2009-10
Résumé
Pulmonary arterial hypertension (PAH) is a disease that causes a narrowing and loss of the blood vessels in the lung, leading to increased stress on the heart and eventual death by heart failure. There are currently no effective treatments for this devastating disease, which often affects individuals in their 30s and 40s and women over men at a ratio of two to one. Current therapies offer patients a partial relief from symptoms, but only marginally extend survival and are extremely expensive (between $20,000 to $200,000 per patient per year, depending on the treatment). Recently, the onset of PAH was linked to a mutation in a gene encoding the protein BMPR-II. While it is still unknown how defects in BMPR-II can lead to disease, the investigation of this relationship remains the best hope for understanding how this disease progresses and for finding an effective treatment.
We believe that mutations in BMPR-II cause disease by altering the functional capacity of endothelial cells, the cells that line the blood vessels. Previous work has been limited by the difficulty associated with isolating endothelial cells from the lungs of both healthy individuals and patients with PAH. However, recent discoveries have led to the development of techniques to isolate circulating stem cells from the blood and drive them towards a cell type that is similar to lung endothelial cells. These techniques offer an alternative cell source from PAH patients that we will use to test the impact of BMPR-II mutations on blood vessel structure, integrity and repair. We will also use advanced genetic techniques to scan the many thousands of genes in the human genetic code and determine how cells isolated from patients with mutations in BMPR-II differ, on a molecular level, from those isolated from healthy individuals. We believe that this work will increase our understanding of PAH and help to identify and test new targets for advanced therapies.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
United Kingdom
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
203286
Name
Ormiston Mark L
Country
United Kingdom
Orgtype
Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Comparative genetic and proteomic analysis of late-outgrowth endothelial progenitor cells from pulmonary arterial hypertension patients bearing mutations in bone morphogenetic protein receptor type II
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Bone Morphogenetic Protein 9; Bone Morphogenetic Protein Receptor Type Ii; Endothelial Cells; Endothelial Progenitor Cells; Pulmonary Arterial Hypertension
Abstract
Pulmonary arterial hypertension (PAH) is a disease that causes a narrowing and loss of the blood vessels in the lung, leading to increased stress on the heart and eventual death by heart failure. There are currently no effective treatments for this devastating disease, which often affects individuals in their 30s and 40s and women over men at a ratio of two to one. Current therapies offer patients a partial relief from symptoms, but only marginally extend survival and are extremely expensive (between $20,000 to $200,000 per patient per year, depending on the treatment). Recently, the onset of PAH was linked to a mutation in a gene encoding the protein BMPR-II. While it is still unknown how defects in BMPR-II can lead to disease, the investigation of this relationship remains the best hope for understanding how this disease progresses and for finding an effective treatment.
We believe that mutations in BMPR-II cause disease by altering the functional capacity of endothelial cells, the cells that line the blood vessels. Previous work has been limited by the difficulty associated with isolating endothelial cells from the lungs of both healthy individuals and patients with PAH. However, recent discoveries have led to the development of techniques to isolate circulating stem cells from the blood and drive them towards a cell type that is similar to lung endothelial cells. These techniques offer an alternative cell source from PAH patients that we will use to test the impact of BMPR-II mutations on blood vessel structure, integrity and repair. We will also use advanced genetic techniques to scan the many thousands of genes in the human genetic code and determine how cells isolated from patients with mutations in BMPR-II differ, on a molecular level, from those isolated from healthy individuals. We believe that this work will increase our understanding of PAH and help to identify and test new targets for advanced therapies.
Competitiondate
201002
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Ormiston, Mark L
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~